Pfizer and biontech receive u.s. fda fast track designation for single-dose mrna-based vaccine candidate against covid-19 and influenza

New york and mainz, germany, december 9, 2022 — pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced the companies have received fast track designation from the u.s. food and drug administration (fda) for their mrna-based combination vaccine candidate for influenza and covid-19, which aims to help prevent two respiratory diseases with a single injection. fast track is a process designed to facilitate the development and expedite the review of new drugs and vaccines intended to treat or prevent serious conditions and address unmet medical need.1
BNTX Ratings Summary
BNTX Quant Ranking